Search Result

Results for "

ALK kinase activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (18) Aldehyde Dehydrogenase (ALDH) (1) Apoptosis (4) Aurora Kinase (1) c-Kit (1) c-Met/HGFR (2) Casein Kinase (1) CDK (1) Checkpoint Kinase (Chk) (1) EGFR (3) FAK (1) HyT (2) Ligands for Target Protein for PROTAC (1) Mitochondrial Metabolism (1) Organoid (2) p38 MAPK (1) Pim (1) PROTACs (2) Reactive Oxygen Species (ROS) (1) Reference Standards (3) RIP kinase (2) TGF-beta/Smad (1) TGF-β Receptor (10) Trk Receptor (1)
By Research Areas:	Cancer (24) Endocrinology (1) Inflammation/Immunology (5)

By Targets:

Anaplastic lymphoma kinase (ALK) (18)

Aldehyde Dehydrogenase (ALDH) (1)

Apoptosis (4)

Aurora Kinase (1)

c-Kit (1)

c-Met/HGFR (2)

Casein Kinase (1)

CDK (1)

Checkpoint Kinase (Chk) (1)

EGFR (3)

FAK (1)

HyT (2)

Ligands for Target Protein for PROTAC (1)

Mitochondrial Metabolism (1)

Organoid (2)

p38 MAPK (1)

Pim (1)

PROTACs (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

RIP kinase (2)

TGF-beta/Smad (1)

TGF-β Receptor (10)

Trk Receptor (1)

By Research Areas:

Cancer (24)

Endocrinology (1)

Inflammation/Immunology (5)

Inhibitors & Agonists

Screening Libraries

Targets Recommended: Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10431

SB-431542 Maximum Cited Publications 294 Publications Verification	Organoid TGF-β Receptor Apoptosis	Cancer
SB-431542 is a *TGF-β receptor kinase* inhibitor (TRKI)*. SB-431542 has inhibitory activity* for ALK4, ALK5 and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

HY-19928

Vactosertib 5+ Cited Publications EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-15841

CEP-37440	Anaplastic lymphoma kinase (ALK) FAK	Cancer
CEP-37440 is a potent, orally active dual *FAK/ALK* inhibitor with IC₅₀ values of 2.3 nM and 3.5 nM for FAK and ALK, respectively. CEP-37440 decreases the cell proliferation by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397) .

HY-13464

ALK-IN-1 Brigatinib analog	Anaplastic lymphoma kinase (ALK) EGFR	Cancer
ALK-IN-1 is an orally active, blood-brain barrier-permeable *ALK* and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .

HY-19928A

Vactosertib Hydrochloride 5+ Cited Publications EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-10431R

SB-431542 (Standard)	Apoptosis TGF-β Receptor Organoid Reference Standards	Cancer
SB-431542 (Standard) is the analytical standard of SB-431542. SB-431542 is a *TGF-β receptor kinase* inhibitor (TRKI)*. SB-431542 has inhibitory activity* for ALK4, ALK5 and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

HY-123919

TL13-112 2 Publications Verification	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-112 is a potent and selective *ALK-PROTAC* degrader and inhibits *ALK* activity with an IC₅₀ value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC₅₀ values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib?(HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .

HY-122582

TL13-12	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-12 is a potent and selective *ALK-PROTAC* degrader and inhibits *ALK* activity with an IC₅₀ value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC₅₀ values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984) .

HY-151289

ALK5-IN-34	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC₅₀ value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-19628

OD36	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36 is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 shows ALK2-directed activity with K_Ds of 37 nM .

HY-16590

X-376 1 Publications Verification	Anaplastic lymphoma kinase (ALK) c-Met/HGFR	Cancer
X-376 is a potent and highly specific *ALK* tyrosine kinase inhibitor (TKI) (IC₅₀=0.61 nM). X-376 is a less potent inhibitor of MET (IC₅₀=0.69 nM). X-376 displays potent anti-tumor activity .

HY-118528A

TP0427736 hydrochloride 2 Publications Verification	TGF-β Receptor	Endocrinology
TP0427736 hydrochloride is a potent inhibitor of *ALK5* kinase activity with an IC₅₀ of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC₅₀=836 nM). TP0427736 hydrochloride also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC₅₀ value of 8.68 nM. TP0427736 hydrochloride can be used for the research of androgenic alopecia (AGA) .

HY-19628A

OD36 hydrochloride	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36hydrochloride is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with K_Ds of 37 nM .

HY-156470

Multi-kinase-IN-6	Trk Receptor Anaplastic lymphoma kinase (ALK) c-Kit EGFR Pim Casein Kinase Checkpoint Kinase (Chk) CDK Apoptosis	Cancer
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, *ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity* against MCF7, HCT116 and EKVX with IC₅₀ values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .

HY-151277

ALK5-IN-29	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-29 is an selective activin receptor-like kinase (ALK) inhibitor. ALK5-IN-29 can inhibit the activity of ALK5 with an IC₅₀ value of ≤10 nM. ALK5-IN-29 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-13464R

ALK-IN-1 (Standard) Brigatinib analog (Standard)	Reference Standards Anaplastic lymphoma kinase (ALK) EGFR	Cancer
ALK-IN-1 (Standard) is the analytical standard of ALK-IN-1 (Brigatinib analog) (HY-13464). This product is intended for research and analytical applications. ALK-IN-1 is an *ALK* and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .

HY-170592

dALK-3	Anaplastic lymphoma kinase (ALK)	Cancer
dALK-3 is an anaplastic lymphoma kinase (ALK) degrader. dALK-3 can effectively induce **EML4-ALK degradation with a DC₅₀** of 0.182 μM. dALK-3 has good anti-proliferation activity against H3122 cells and can be used in the study of cancer .

HY-131909

CJ-2360	Anaplastic lymphoma kinase (ALK)	Cancer
CJ-2360 is a potent and orally active *ALK* inhibitor with IC₅₀s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated .

HY-161910

SH-E4A-66	Anaplastic lymphoma kinase (ALK)	Cancer
SH-E4A-66 is a C ²-COUPLr (COvalent Protein Ligator) with carbazole scaffold barring heterogeneous cysteine reactive warheads (acrylamide and chloroacetamide). SH-E4A-66 is capable of coupling with *EML4-ALK* (EC₅₀=1.5 μM) and inhibiting the activity of *EML4-ALK* kinase (IC₅₀=2.3 μM) .

HY-163429

J-1149	TGF-β Receptor p38 MAPK	Inflammation/Immunology Cancer
J-1149 is a potent *ALK5* inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research .

HY-16590R

X-376 (Standard)	Reference Standards Anaplastic lymphoma kinase (ALK) c-Met/HGFR	Cancer
X-376 (Standard) is the analytical standard of X-376. This product is intended for research and analytical applications. X-376 is a potent and highly specific *ALK* tyrosine kinase inhibitor (TKI) (IC₅₀=0.61 nM). X-376 is a less potent inhibitor of MET (IC₅₀=0.69 nM). X-376 displays potent anti-tumor activity .

HY-182057

ALK degrader 4	HyT Anaplastic lymphoma kinase (ALK)	Cancer
ALK degrader 4 is a ALK HyT degrader with an IC₅₀ of 0.74 nM. ALK degrader 4 inhibits *ALK* kinase activity, increases the solvent-accessible surface area of hydrophobic residues near the *ALK* binding pocket, promotes *ALK* to form a partially unfolded conformation, and induces proteasomal degradation of *ALK. ALK* degrader 4 inhibits cancer cell proliferation. ALK degrader 4 can be used in research related to non-small cell lung cancer (ALK ligand: Brigatinib (HY-12857); hydrophobic tag: Norbornene (HY-W013021)) .

HY-183767

Aurora kinase/ALK-IN-1	Aurora Kinase Anaplastic lymphoma kinase (ALK) Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) Aldehyde Dehydrogenase (ALDH)	Cancer
Aurora kinase/ALK-IN-1 is a dual Aurora A kinase and *ALK* inhibitor with IC₅₀ values of 0.296 μM and 0.332 μM, respectively. Aurora kinase/ALK-IN-1 induces G₂/M cell cycle arrest, triggers mitochondrial apoptosis, elevates intracellular reactive oxygen species (ROS) levels, and inhibits ALDH1 activity. Aurora kinase/ALK-IN-1 demonstrates cytotoxicity and tumor selectivity. Aurora kinase/ALK-IN-1 can be used for the research of anaplastic large cell lymphoma .

HY-181113

ALK-IN-34	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-34 is an Anaplastic Lymphoma Kinase (ALK) inhibitor with an IC₅₀ of 0.26 μM. ALK-IN-34 demonstrates antiproliferative activity against lung cancer cells and gastric adenocarcinoma cells .

HY-183441

ALK5 ligand-1	Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK)	Inflammation/Immunology
ALK5 ligand-1 (a31's ALK5 ligand) is a ligand of Anaplastic lymphoma kinase *ALK5* with higher selectivity for ALK5 than for ALK4. ALK5 ligand-1 can be used to synthesize PROTAC degraders targeting ALK5. ALK5 PROTACs induce *ALK5* degradation dependent on the ubiquitin-proteasome system and exert antifibrotic activity. ALK5 ligand-1 can be used in studies of pulmonary fibrosis .

HY-182087

ALK degrader 3	HyT Anaplastic lymphoma kinase (ALK)	Cancer
ALK degrader 3 is a ALK HyT degrader with an IC₅₀ of 1.2 nM. ALK degrader 3 inhibits *ALK* kinase activity, increases the solvent-accessible surface area of hydrophobic residues near the *ALK* binding pocket, promotes *ALK* to form a partially unfolded conformation, and drives *ALK* degradation via the proteasomal pathway. ALK degrader 3 inhibits the proliferation of tumor cells. ALK degrader 3 can be used for the research of non-small cell lung cancer. (ALK ligand: Brigatinib (HY-12857); hydrophobic tag: Tetraasterane (HY-W1139353)) .

HY-116636

KRCA-0377	Anaplastic lymphoma kinase (ALK)	Cancer
KRCA-0377 is an orally active ALK inhibitor with an IC₅₀ of 0.001 μM. KRCA-0377 also inhibits mutant ALK enzyme with IC50 values ≤0.01 μM. KRCA-0377 shows cytotoxicity against cancer cells and inhibits tumor growth in xenograft mice models. KRCA-0377 can be used for the research of ALK-positive non-small-cell lung cancer .

HY-185430

HM-279	TGF-β Receptor	Inflammation/Immunology Cancer
HM-279 is a potent and orally active *ALK5* inhibitor with an IC₅₀ of 4.7 nM. HM-279 shows cross-reactivity with *ALK7* (IC₅₀ = 6.8 nM), but HM-279 has fair to good selectivity against other TGF-β receptor family kinases, with 4.5-693-fold selectivity. HM-279 demonstrates antitumor activity in vivo through CD8 ⁺ T cell immunity. HM-279 can be used for the research of colon cancer .

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library	2,886 compounds
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 2,886 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Anti-Lung Cancer Compound Library

2,886 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,886 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.